Antimonopoly worries scupper Mediceo/Paltac merger in Japanese wholesaling sector
This article was originally published in Scrip
Official concerns over fair competition appear to be behind a decision by Japanese pharmaceutical wholesaling giants Mediceo Paltac Holdings and Alfresa Holdings to scrap their planned April 1st merger.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.